Intuitive Surgical (NASDAQ:ISRG) Posts Earnings Results, Beats Expectations By $0.17 EPS

Intuitive Surgical (NASDAQ:ISRG) posted its earnings results on Thursday. The medical equipment provider reported $1.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.76 by $0.17, Zacks reports. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%.

Intuitive Surgical Trading Down 0.3 %

ISRG traded down $1.79 on Thursday, hitting $608.66. The company had a trading volume of 2,226,284 shares, compared to its average volume of 1,813,992. The company’s fifty day moving average price is $544.61 and its 200 day moving average price is $502.64. Intuitive Surgical has a 1 year low of $362.14 and a 1 year high of $616.00. The firm has a market cap of $216.79 billion, a P/E ratio of 97.86, a PEG ratio of 5.13 and a beta of 1.39.

Insiders Place Their Bets

In other Intuitive Surgical news, EVP Robert Desantis sold 188 shares of Intuitive Surgical stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $506.52, for a total value of $95,225.76. Following the completion of the transaction, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at $2,788,899.12. The trade was a 3.30 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Gary S. Guthart sold 18,151 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $511.63, for a total transaction of $9,286,596.13. Following the completion of the transaction, the chief executive officer now directly owns 24,219 shares of the company’s stock, valued at approximately $12,391,166.97. The trade was a 42.84 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 43,487 shares of company stock valued at $22,590,975 over the last 90 days. 0.90% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $538.00 price objective (up previously from $495.00) on shares of Intuitive Surgical in a report on Friday, October 18th. Truist Financial increased their price target on Intuitive Surgical from $570.00 to $640.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Stifel Nicolaus boosted their price objective on Intuitive Surgical from $525.00 to $610.00 and gave the company a “buy” rating in a research report on Thursday, December 5th. Mizuho increased their target price on Intuitive Surgical from $440.00 to $500.00 in a research report on Thursday, October 17th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Intuitive Surgical from $495.00 to $575.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and a consensus price target of $554.17.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.